drugset

drugset / Trial / NCT06393972

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

NCT06393972 ↗

Phase 2 Not yet recruiting 25 enrolled Shanghai Zhongshan Hospital

NaSingle-groupOpen-labelTreatment

Summary

The efficacy and safety of Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a single-arm, prospective, phase 2 trial

Timeline

Start: 2024-07-01
Primary completion: 2025-11-30
Completion: 2026-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tofacitinib	Small molecule	5 mg	—

Indications